Benchling

That feeling when people come to your events... wearing your swag. 🧦💕

🇫🇷 Scenes from the French #biotech community: Yesterday, over 100 scientists, developers, and innovators came together to share ideas, make new connections, and discuss strategies for modernizing — and importantly, accelerating — their R&D. It was inspiring to see everyone — across #biopharma, biomaterials, future foods, and more — coming together with such enthusiasm. What was even more powerful was the eagerness to exchange insights and advance digital transformation as a community. Key topics included #AI-reinforced antibody discovery, automated data management, and API-driven infrastructure 👏 Thanks to everyone who joined us for Digital Science & Innovation Day in Paris! Special thanks to our amazing speakers: Elodie Pronier (Owkin) Jean-Louis Honeine (Benchling) Johanna Michielin (BioLabs) Maya Bendifallah, PhD (Nutropy) Meritxell Orpinell, PhD, PMP (Benchling) Patrick Torbey (Neoplants) peggy willemarck (Sanofi) Pierre Salvy (Cambrium) Radoslaw Ejsmont (SYNOVANCE) Sylvain Yon (Mabqi) Suchitra Ramaswamy (Zifo)

"One of the major challenges we are tackling [in adopting AI] is modernizing our legacy systems and stitching together data that is coming from a lot of different places," said Will Weiss, AVP Biotechnology Discovery Research at Eli Lilly and Company. Much of #biopharma is still struggling with this — 43% of large biopharma #IT support 20+ different scientific software applications, many of which are custom-built.   Learn about the tech strategies that large and small biopharma are adopting to pave the way for #AI readiness: https://lnkd.in/evS3D4XS

Benchling’s State of Tech in Biopharm Part 2: David vs Goliath This year’s report focused mainly on the differences between big and small biopharm companies adoption/deployment of various technologies. As someone who has spent the last 6+ years in small biotechs (and the previous 6+ years at a fortune 50), many of these findings rang true. Small companies have significantly different priorities and resources, especially in the post-Covid biotech environment. The report found these differences were most drastic in AI/ML deployment and Lab Automation. In the lab automation space, deployment at a small biotech can be difficult. Capital is often tighter, timelines more urgent, and the science can be less established. I have been fortunate to be at biotechs where lab automation has been a core strategy and priority, but the report shows that is not the case for 73% of small biotechs. I keep thinking that cloud labs/hybrid cloud labs will one day fill this gap. There has to be a way for early stage companies to establish the cultural and scientific benefits of lab automation without taking on all the capital investment and timeline risks. One of these days it will happen!

How do you move drug candidates through the pipeline faster? SNIPR Biome - A CRISPR Company is pioneering the discovery and development of #CRISPR-based microbiome drugs — with all their R&D data on a single end-to-end platform. We’re proud to have served SNIPR Biome from nearly the beginning. See why building a strong data foundation accelerates time to milestone: https://lnkd.in/etU6PapW #BuiltOnBenchling

I got 96 problems, but a map ain’t one. Plate maps are here! 👉 Find out how to visualize and annotate wells in Benchling, using an easy, intuitive interface: https://lnkd.in/ghKAxBDJ 👀 See what else is new: https://lnkd.in/eQecRPSR #FeatureFriday

What a difference a year makes! Every year Benchling puts together a terrific "State of Tech in Biopharma" report. If you have not read it, I would highly recommend you do (link in the comments) and I will likely put together a couple posts on this report. This year the report focused on the strategic differences between large biopharma (>1000 employees) and small biopharma, focusing on how they deploy five components of an enabling tech stack: - R&D data platform: Think Benchling or others - SaaS: Cloud-based scientific applications - AI/ML for science: AlphaFold, RFdiffusion, others - Connected lab instruments: Automated data collection - Robotics and Automation Being me, I skipped ahead to the Robotics and Automation section. My first takeaway was how much Robotics and Automation has fallen out of favor in just a year. In 2023, Robotics and Automation ranked #2 in "Longer-term investment priorities" within R&D. In 2024, that rank drops to the basement at #5. I will drop a few of my ideas on why in the comments, but I am curious why you think that is?

Discover how Constructive Bio is building beyond nature to create the next generation of biomolecules. Using synthetic genomes and non-canonical amino acids, this UK-based biotech is developing therapeutics with enhanced molecular and chemical properties. Just look at drugs like Wegovy and Ozempic — their active ingredient semaglutide incorporates a non-canonical amino acid to improve drug stability. Now imagine how this technology will expand the toolkit available not only for drug development, but across industries. With Constructive’s ability to design molecules with unprecedented specificity and fidelity, they’re unlocking the next generation of biologics — and doing so in a more sustainable and scalable way. See how they’re using Benchling to centralize their data and scale their R&D. We’re proud to support their mission! 🧬🧑🔬 https://lnkd.in/emjEFqAz #BuiltOnBenchling

#JeffyP is on a roll! 🎲 Thanks to the Bay Area #biotech community for joining us (and our lovable mascot) at #BenchBreak. It was an energizing afternoon of product updates, hands-on workshops, and even a casino-themed happy hour! Missed it? No worries — sign up to hear about future events: https://lnkd.in/efYjVdqC

What is the single most important technology when it comes to modernizing your R&D and accelerating scientific impact? We asked hundreds of #biopharma which technologies they’re investing in — their answers surprised us. See why large and small biopharma are betting on different tech strategies. 👉 Download the report: https://lnkd.in/evS3D4XS